D. E. Shaw & Co., Inc. Erasca, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 483,826 shares of ERAS stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
483,826Holding current value
$1.23 Million% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$49.4 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$42.9 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$41.4 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35.1 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$33.9 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $311M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...